Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P. Morelli E, et al. Among authors: fulciniti m. Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11. Blood. 2018. PMID: 29997223 Free PMC article.
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC. Shammas MA, et al. Among authors: fulciniti m. Blood. 2006 Oct 15;108(8):2804-10. doi: 10.1182/blood-2006-05-022814. Epub 2006 Jun 29. Blood. 2006. PMID: 16809610 Free PMC article.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Chauhan D, et al. Among authors: fulciniti m. Blood. 2007 Feb 1;109(3):1220-7. doi: 10.1182/blood-2006-04-015149. Epub 2006 Oct 10. Blood. 2007. PMID: 17032924 Free PMC article.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Tai YT, et al. Among authors: fulciniti m. Blood. 2007 Sep 1;110(5):1656-63. doi: 10.1182/blood-2007-03-081240. Epub 2007 May 17. Blood. 2007. Retraction in: Blood. 2024 Oct 10;144(15):1648. doi: 10.1182/blood.2024026818 PMID: 17510321 Free PMC article. Retracted. Clinical Trial.
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC. Shammas MA, et al. Among authors: fulciniti m. Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81. Epub 2008 May 1. Leukemia. 2008. PMID: 18449204 Free PMC article.
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC. Tai YT, et al. Among authors: fulciniti m. Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Blood. 2009. Retraction in: Blood. 2010 Apr 8;115(14):2983. doi: 10.1182/blood-2010-03-273136 PMID: 19196658 Free PMC article. Retracted.
103 results